These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. [Déjà vu: elaboration of a hypothetical model of explanation]. de Nayer A Psychiatr Clin (Basel); 1979; 12(2):92-6. PubMed ID: 515449 [TBL] [Abstract][Full Text] [Related]
26. "Where or when": still mystery and magic in the guise of "déjà vu". Kohn SR J Med Soc N J; 1979 Feb; 76(2):101-4. PubMed ID: 284149 [No Abstract] [Full Text] [Related]
27. Case histories, magic bullets and the state of drug discovery. Drews J Nat Rev Drug Discov; 2006 Aug; 5(8):635-40. PubMed ID: 16883301 [TBL] [Abstract][Full Text] [Related]
28. Persistent déjà vu associated with temporal lobe epilepsy in an adolescent. Akgül S; Oksüz-Kanbur N; Turanlı G Turk J Pediatr; 2013; 55(5):552-4. PubMed ID: 24382542 [TBL] [Abstract][Full Text] [Related]
29. Déjà vu in the laboratory: a behavioral and experiential comparison of posthypnotic amnesia and posthypnotic familiarity. O'Connor AR; Barnier AJ; Cox RE Int J Clin Exp Hypn; 2008 Oct; 56(4):425-50. PubMed ID: 18726806 [TBL] [Abstract][Full Text] [Related]
31. Normal patterns of déjà experience in a healthy, blind male: challenging optical pathway delay theory. O'Connor AR; Moulin CJ Brain Cogn; 2006 Dec; 62(3):246-9. PubMed ID: 16890338 [TBL] [Abstract][Full Text] [Related]
32. Quality control of radiolabeled monoclonal antibodies. Khazaeli MB Cancer Biother Radiopharm; 2000 Dec; 15(6):529-30. PubMed ID: 11190485 [No Abstract] [Full Text] [Related]
33. [From magic bullets to real drugs--immunotherapy available on the pharmacy's shelves]. Veromaa T Duodecim; 2003; 119(8):793-800. PubMed ID: 12806743 [No Abstract] [Full Text] [Related]
34. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis. Knogler K; Grünberg J; Zimmermann K; Cohrs S; Honer M; Ametamey S; Altevogt P; Fogel M; Schubiger PA; Novak-Hofer I Clin Cancer Res; 2007 Jan; 13(2 Pt 1):603-11. PubMed ID: 17255283 [TBL] [Abstract][Full Text] [Related]
35. Empirical research on déjà vu experiences: a review. Sno HN; Schalken HF; de Jonghe F Behav Neurol; 1992; 5(3):155-60. PubMed ID: 24487740 [TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibody therapy of cancer. Jurcic JG; Scheinberg DA; Houghton AN Cancer Chemother Biol Response Modif; 1997; 17():195-216. PubMed ID: 9551215 [No Abstract] [Full Text] [Related]
37. A revolution in the treatment of non-Hodgkin's lymphoma. DeNardo GL; O'Donnell RT; Oldham RK; DeNardo SJ Cancer Biother Radiopharm; 1998 Aug; 13(4):213-23. PubMed ID: 10850358 [TBL] [Abstract][Full Text] [Related]
38. Monoclonal antibodies, cytokines and fusion proteins in the treatment of malignant disease. Hank JA; Albertini MR; Sondel PM Cancer Chemother Biol Response Modif; 1999; 18():210-22. PubMed ID: 10800484 [No Abstract] [Full Text] [Related]
39. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264 [TBL] [Abstract][Full Text] [Related]
40. [The phenomenon of deja vu in psychopathology and literature]. Farina B; Verrienti D Minerva Psichiatr; 1996 Jun; 37(2):99-106. PubMed ID: 8926863 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]